Autism Spectrum Disorder (ASD) Clinical Trial
— VIDEOTSAOfficial title:
Evaluation of the Videodrama Therapeutic Device for Children With Autism Spectrum Disorders
Autism spectrum disorder (ASD) is a neurodevelopmental disorder (Valerie, Sperenza, 2009) that begins early in development, characterized by persistent deficits in communication and social interactions across various contexts and restricted, repetitive patterns of behavior, interests, or activities. These symptoms significantly impact social, school/professional functioning, or other important areas and are not better explained by intellectual disability or global developmental delay (American Psychiatric Association, 2013).
Status | Recruiting |
Enrollment | 30 |
Est. completion date | March 4, 2027 |
Est. primary completion date | March 4, 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 3 Years to 12 Years |
Eligibility | Inclusion Criteria: - Children aged 3 to 12 years. - Clinically confirmed ASD by a psychiatrist. - Parental or legal guardian consent for participation. - Child showing a strong interest in screens and/or video content. - Ability to tolerate the presence of other children. - Minimum of 9 video drama sessions. - Not having benefited from disease care in the past. - Affiliation to a social security system Exclusion Criteria: - No ASD diagnosis. - Younger than 3 or older than 12 at the study start. - No interest in screens or video content. - Parental or legal guardian refusal for participation. - Dropping out before completing 9 sessions. - Patient having benefited a disease care in the past |
Country | Name | City | State |
---|---|---|---|
France | CHI Robert Ballanger | Aulnays-sous-bois |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Intercommunal Robert Ballanger |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Dunn Sensory Profile questionnaire | Sensory atypicality frequency will be assessed using the Dunn Sensory Profile questionnaire, describing child behavior in various sensory experiences | 9 months | |
Secondary | Cars-T questionnaire | Observe improvements in social skills (interaction and communication) in children with ASD, assessed by the Cars-T questionnaire, | 9 months | |
Secondary | Sceno Test | Observation of the emergence of a symbolic game. This emergence will be evaluated by the passation of the scenotest, a test which reveals the different modalities of integration of the game. | 9 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03715166 -
Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder
|
Phase 3 | |
Not yet recruiting |
NCT05182697 -
SCI-210 in the Treatment of Children and Young Adults With AutismEvaluate the Safety, Tolerability and Efficacy of SCI-210 in Children With Autism Spectrum Disorder (ASD)
|
N/A | |
Completed |
NCT02803801 -
Build Your Parenting Toolkit: Guiding Children to Become Flexible Thinkers
|
N/A | |
Recruiting |
NCT04376151 -
Guided ACT and for Adults With ASD
|
N/A | |
Terminated |
NCT03715153 -
Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.
|
Phase 3 | |
Terminated |
NCT01592773 -
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
|
Phase 2 | |
Withdrawn |
NCT01395953 -
Double-blind Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders
|
Phase 2 | |
Terminated |
NCT01248130 -
Omega-3 Fatty Acids Monotherapy in Children and Adolescents With Autism Spectrum Disorders
|
Phase 2 | |
Completed |
NCT04860986 -
A Repeatability and Reproducibility Study of the EarliPointâ„¢ Device
|
||
Completed |
NCT04299464 -
A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)
|
Phase 2 | |
Recruiting |
NCT03392870 -
Evaluation of a Clinical Transitional Program in Autism
|
N/A | |
Completed |
NCT01592786 -
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
|
Phase 2 | |
Enrolling by invitation |
NCT05187377 -
A Controlled Trial of Growth Hormone in Phelan-McDermid Syndrome and Idiopathic Autism
|
Phase 2 | |
Completed |
NCT04631432 -
Choice Switching and Autism
|
||
Recruiting |
NCT04578756 -
Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder
|
Phase 3 | |
Completed |
NCT02037022 -
Pivotal Response Treatment Package for Young Children With Autism
|
N/A | |
Completed |
NCT01854346 -
Social Skills Group Training ("KONTAKT") for Children and Adolescent With High-functioning Autism Spectrum Disorders
|
N/A | |
Active, not recruiting |
NCT04895215 -
AB-2004 in Treatment of Irritability Associated With Autism Spectrum Disorder (ASD)
|
Phase 2 | |
Active, not recruiting |
NCT03426826 -
The Gut-Brain Study
|
Phase 1 | |
Completed |
NCT02384486 -
Efficacy of Training Programme to Reduce Stress
|
N/A |